DEEPMIND SPINOUT RAISES $2.1 BILLION TO DESIGN DRUGS WITH AI — FIRST CLINICAL TRIALS BY END OF YEAR Isomorphic Labs, the AI drug design company spun out of Google DeepMind by CEO Demis Hassabis, has closed a $2.1 billion Series B funding round led by Thrive Capital. Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund all participated. The round brings total outside capital raised to roughly $2.7 billion across two rounds. The money goes toward scaling what Isomorphic calls its AI drug design engine — software that can model protein structures, predict drug interactions, and generate therapeutic candidates at a speed and precision no human team can match. The company says its first AI-designed drugs are now expected to enter clinical trials before the end of 2026. That is a milestone that would have seemed implausible five years ago. Drug discovery is one of the most expensive, time-consuming processes in all of science. A single approved drug typically takes 10 to 15 years and over a billion dollars to develop. AI is compressing that timeline in ways that are only beginning to be understood. The sovereign wealth fund participation — UK Sovereign AI Fund, Temasek, MGX — signals that governments and state investors are no longer watching AI’s healthcare ambitions from the sidelines. They are putting capital to work in a race to own the infrastructure of AI-driven medicine before the first blockbuster hits the market. Keywords: Isomorphic Labs funding, AI drug discovery 2026, DeepMind AI medicine, AI clinical trials